Centene Corporation
- Jurisdiction
United States - LEI
549300Z7JJ4TQSQGT333 - ISIN
US15135B1017 (CNC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€42.24 29.1% undervalued - Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Read full profile
Fundamentals
- Net revenue
€151.99B - Gross margin
12.5% - EBIT
€1.63B - EBIT margin
1.1% - Net income
€1.75B - Net margin
1.2%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| LONDON SARAH | Chief Executive Officer |
|
|
|
|
| Samuels Theodore R. II | N/A |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | September 12, 2025 | $1.00K–$15.00K |
| Val Hoyle | September 12, 2025 | $1.00K–$15.00K |
| Tim Moore | September 3, 2025 | $16.00K–$65.00K |
| Tim Moore | September 3, 2025 | $100.00K–$250.00K |
| Tim Moore | August 5, 2025 | $16.00K–$65.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Ray Dalio |
|
|
|
Sell |